Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luuk Gras

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Plos One|April 5, 2014
Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatmentMarlous L Grijsen, Ferdinand W N M Wit, Suzanne Jurriaans, et al.
Antiviral Therapy|August 23, 2012
No advantage of quadruple- or triple-class antiretroviral therapy as initial treatment in patients with very high viraemiaMarlous L Grijsen, Rebecca Holman, Luuk Gras, et al.
AIDS (London, England)|April 9, 2009
Clinical experience with the combined use of lopinavir/ritonavir and rifampicinRafaëlla Fa L'homme, Hanneke M J Nijland, Luuk Gras, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2008
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort studyFerdinand W N M Wit, Anouk M Kesselring, Luuk Gras, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2007
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greaterLuuk Gras, Anouk M Kesselring, James T Griffin, et al.
AIDS (London, England)|November 18, 2011
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmissionJoshua T Herbeck, Viktor Müller, Brandon S Maust, et al.
AIDS (London, England)|April 11, 2006
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapyJolanda G M Hoefnagel, Manon J van der Lee, Peter P Koopmans, et al.
Plos Medicine|November 4, 2015
Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic AnalysisDaniela Bezemer, Anne Cori, Oliver Ratmann, et al.
AIDS (London, England)|August 24, 2011
Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 controlDaniëlle van Manen, Luuk Gras, Brigitte D Boeser-Nunnink, et al.
Brain : a Journal of Neurology|March 25, 2020
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort studyFrank de Wolf, Mohsen Ghanbari, Silvan Licher, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Plos One|April 5, 2014
Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatmentMarlous L Grijsen, Ferdinand W N M Wit, Suzanne Jurriaans, et al.
Antiviral Therapy|August 23, 2012
No advantage of quadruple- or triple-class antiretroviral therapy as initial treatment in patients with very high viraemiaMarlous L Grijsen, Rebecca Holman, Luuk Gras, et al.
AIDS (London, England)|April 9, 2009
Clinical experience with the combined use of lopinavir/ritonavir and rifampicinRafaëlla Fa L'homme, Hanneke M J Nijland, Luuk Gras, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2008
Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients: the ATHENA cohort studyFerdinand W N M Wit, Anouk M Kesselring, Luuk Gras, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 7, 2007
CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greaterLuuk Gras, Anouk M Kesselring, James T Griffin, et al.
AIDS (London, England)|November 18, 2011
Is the virulence of HIV changing? A meta-analysis of trends in prognostic markers of HIV disease progression and transmissionJoshua T Herbeck, Viktor Müller, Brandon S Maust, et al.
AIDS (London, England)|April 11, 2006
The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapyJolanda G M Hoefnagel, Manon J van der Lee, Peter P Koopmans, et al.
Plos Medicine|November 4, 2015
Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic AnalysisDaniela Bezemer, Anne Cori, Oliver Ratmann, et al.
AIDS (London, England)|August 24, 2011
Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 controlDaniëlle van Manen, Luuk Gras, Brigitte D Boeser-Nunnink, et al.
Brain : a Journal of Neurology|March 25, 2020
Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort studyFrank de Wolf, Mohsen Ghanbari, Silvan Licher, et al.
Pageof 8